Abstract
Background/Aim: Estrogen receptor alpha (ER alpha) antagonist is the most common treatment for ER alpha-positive breast cancer. However, compensatory ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
